XT
ZNTL icon

XTX Topco’s Zentalis Pharmaceuticals ZNTL Stock Holding History

XTX Topco’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$755K Sell
322,507
-254,200
-44% -$656K 0.01% 1664
2025
Q4 		$779K Buy
576,707
+28,078
+5% +$40.9K 0.02% 1215
2025
Q3 		$828K Buy
548,629
+283,800
+107% +$425K 0.04% 695
2025
Q2 		$307K Buy
264,829
+140,433
+113% +$185K 0.01% 1413
2025
Q1 		$198K Buy
124,396
+1,408
+1% +$3.04K 0.01% 1708
2024
Q4 		$373K Sell
122,988
-71,074
-37% -$233K 0.03% 1029
2024
Q3 		$714K Buy
194,062
+15,597
+9% +$56.7K 0.05% 590
2024
Q2 		$730K Buy
178,465
+167,854
+1,582% +$1.87M 0.06% 484
2024
Q1 		$167K Buy
+10,611
New +$146K 0.02% 1230
2023
Q4 		– Sell
-19,008
Closed -$381K – 2235
2023
Q3 		$381K Buy
+19,008
New +$482K 0.07% 571
2023
Q2 		– Sell
-21,215
Closed -$365K – 1911
2023
Q1 		$365K Buy
+21,215
New +$430K 0.08% 498
2022
Q4 		– Sell
-9,655
Closed -$209K – 1567
2022
Q3 		$209K Buy
+9,655
New +$264K 0.05% 753

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

XTX Topco's ZNTL Position: Q1 2026 in Review

XTX Topco reduced its Zentalis Pharmaceuticals (ZNTL) stake by 44% in Q1 2026, selling an estimated $656K and leaving 322,507 shares worth $755K. The position accounts for 0.01% of the portfolio, ranked #1664.

XTX Topco first reported a position in ZNTL in Q3 2022 and has held it in 12 quarters since. The position peaked at $828K in Q3 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • XTX Topco held 322,507 shares of Zentalis Pharmaceuticals worth $755K as of Q1 2026.
  • XTX Topco sold 254,200 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $656K.
  • Zentalis Pharmaceuticals made up 0.01% of XTX Topco's portfolio in Q1 2026, its #1664 holding.
  • XTX Topco first reported a position in Zentalis Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
  • XTX Topco's Zentalis Pharmaceuticals position peaked at $828K in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.